CBD and Drug Testing: Work, Driving, Sports 2026

The question "will CBD show up in a drug test" is today one of the most frequently asked by cannabis consumers in Poland. The reason is simple. Preventive tests at work have become routine for professional drivers, machine operators, construction workers, and uniformed services. The standard SAMHSA threshold for the THC-COOH metabolite in urine is 50 ng/mL (SAMHSA Mandatory Guidelines, 2023). This is a level that cannabidiol does not exceed, but trace amounts of THC from full spectrum oils can exceed.

In this guide, we break down the topic into its components. We show exactly what drug tests are looking for, how the distinction between immunoassay and GC-MS works, how Polish labor law treats the presence of cannabinoids, and why athletes have a different threshold than employees. We base our findings on data from SAMHSA, JAMA Psychiatry, AACC, Drug Test Anal, ISAP, WADA, and USADA. Each statement has a source, allowing you to verify the foundations yourself.

This material is directed at adults who want to use CBD legally and safely. That is, those who cannot afford a positive screening at work, on the road, or in competitions. We will show you how to choose a broad spectrum product with 0% THC, how to read a COA, what to do in case of a control, and how to document your supplementation. A practical checklist at the end will help you implement these recommendations in your daily life.

KEY INFORMATION
– CBD and THC are two different cannabinoids. Tests look for THC-COOH, not CBD. The SAMHSA threshold is 50 ng/mL for employees and 150 ng/mL for athletes (SAMHSA, 2023).
– Broad spectrum 0% THC eliminates the risk of detection. Full spectrum with 0.2-0.3% THC can yield a positive result with regular dosing (Spindle, JAMA Psychiatry, 2019).
– The Polish Labor Code Article 221b allows employers to conduct preventive sobriety checks and the presence of intoxicants. The procedure requires a company regulation.
– Article 178a of the Penal Code punishes driving a vehicle under the influence of THC. Saliva and blood tests are standards used by the Polish road police.
– WADA removed CBD from the list of prohibited substances in 2018, but THC and other cannabinoids remain banned in competitions (WADA, 2018).

What exactly do standard drug tests look for?

Drug tests do not look for CBD. The target substance in the cannabis panel is the THC metabolite, specifically 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, abbreviated as THC-COOH. The standard detection threshold in urine according to SAMHSA Mandatory Guidelines is 50 ng/mL at the screening level and 15 ng/mL at the GC-MS confirmation level (SAMHSA, 2023). This is a global standard adopted by accredited Polish laboratories.

Why THC-COOH and not just THC? Active THC has a short detection window in the blood, only 2-12 hours. Its inactive metabolite, THC-COOH, which accumulates in fatty tissue, remains much longer. This makes it a convenient marker for cannabis exposure, whether it involves marijuana or trace THC in full spectrum CBD oil.

The standard drug test panel usually includes 5 or 10 substances. In a 5-panel set, we have: amphetamines, cocaine, opiates, phencyclidine, and cannabinoids. The 10-panel adds benzodiazepines, barbiturates, methaqualone, methadone, and propoxyphene. CBD does not appear on any of these lists as a target substance because it has no psychoactive effects or addictive potential.

Can CBD indirectly affect the result? Yes, but only if the product contains trace THC. Pure cannabidiol in broad spectrum 0% THC will not trigger a test reaction. The problem arises with full spectrum oils with a legally permissible content of up to 0.3% THC. With intensive dosing, these traces can accumulate in the body to the detection threshold.

Types of biological samples

Urine is the most popular sample because it is inexpensive, easy to collect, and provides a long detection window of 3-30 days. Blood shows active exposure, meaning the last 2-12 hours. Saliva has a window of 1-24 hours and is the standard for road police in Poland. Hair can show use up to 90 days back, but it is costly and rarely used.

Sweat, nails, and breast milk are niche samples, mainly used in scientific research or special legal proceedings. In everyday life, you will mainly encounter urine tests (work), saliva tests (drivers), or blood tests (retesting after a traffic accident). Each has a different threshold, methodology, and risk of false results.

Cut-off thresholds in different contexts

Civilian employee: 50 ng/mL screening, 15 ng/mL confirmation GC-MS (SAMHSA, 2023). WADA athlete: 150 ng/mL THC-COOH in urine, indicating a higher tolerance for „everyday life” (USADA, 2024). Driver in Poland: no statutory threshold, any presence of THC can be treated as „under the influence” according to Article 178a of the Penal Code. The so-called zero tolerance is controversial but is in effect.

Employees of uniformed services and strategic sectors (police, military, nuclear energy) may be subject to lower thresholds, sometimes 25 ng/mL at screening. These are internal employer regulations that exceed the SAMHSA standard. Check your workplace regulations if you work in such an industry.

The standard cut-off threshold for THC-COOH in the urine of an employee is 50 ng/mL at the immunoassay screening stage and 15 ng/mL after GC-MS confirmation (SAMHSA Mandatory Guidelines, 2023). Athletes affiliated with WADA have a higher threshold of 150 ng/mL, reflecting tolerance for passive exposure and previous use outside of competition.

How does CBD differ from THC in terms of drug tests?

CBD and THC have the same molecular formula C21H30O2, but different molecular geometry. This difference determines everything. THC binds strongly to the CB1 receptor in the brain, producing a psychoactive effect. CBD binds weakly and does not cause intoxication (PMC, Frontiers in Pharmacology, 2020). For drug tests, the presence of THC-COOH matters, not CBD.

Cannabidiol does not metabolize into THC-COOH in the human body. This is a key fact confirmed by pharmacokinetic studies. Pure CBD does not convert into active THC or its metabolite under any physiological conditions. The old theory of „conversion of CBD to THC in the stomach” has been debunked by in vivo studies (Cannabis and Cannabinoid Research, 2017).

The problem arises only when a CBD product contains traces of THC. The Polish limit for hemp is 0.3% THC (Journal of Laws 2005 No. 179 item 1485). This may seem like a small amount, but with regular, intensive dosing, THC accumulation in fatty tissue can reach the detection level. Therefore, distinguishing the type of product is crucial.

Three basic types of CBD extracts differ in THC content. Isolate: 99% pure CBD, 0% THC. Broad spectrum: full cannabinoid profile except THC, certified 0% THC. Full spectrum: all cannabinoids including THC up to 0.3%. Only the first two types are safe for those tested at work or in sports.

The metabolic mechanism of THC in the body

After ingestion, cytochrome P450 enzymes (mainly CYP2C9 and CYP3A4) convert THC into 11-OH-THC and then into THC-COOH. The latter is psychoactively inactive but lipophilic, meaning it dissolves in fats. Therefore, it accumulates in fatty tissue and is gradually released over days or weeks after exposure.

The half-life of THC-COOH is 1-3 days for occasional users and 5-13 days for regular users (Journal of Analytical Toxicology, 2019). This explains why the detection window extends with frequency of use. A person who took full spectrum oil once will clear THC from their system in 3-5 days. Someone who takes it daily for a month may test positive for 30 days after stopping.

Why does CBD itself not produce a positive result?

Modern immunoassay tests use monoclonal antibodies that recognize the specific molecular structure of THC-COOH. Although CBD has a similar formula, its geometry is different enough that the antibodies do not react (AACC, 2022). This is the difference between classic tests from the 80s and current, much more specific ones.

Cross-reactivity is very rare today. CBD would have to be present in concentrations a million times higher than therapeutic doses to interfere with the test. This is a level impossible to achieve in real life. Therefore, the mere act of taking CBD does not generate a false positive in a modern laboratory.

How does SAMHSA 50 ng/mL work and why is it a global standard?

The 50 ng/mL THC-COOH threshold for immunoassay and 15 ng/mL for GC-MS comes from the American Mandatory Guidelines for Federal Workplace Drug Testing Programs developed by SAMHSA (Substance Abuse and Mental Health Services Administration) (SAMHSA, 2023). This is a reference document for most laboratories worldwide, including Polish ISO/IEC 17025 accredited facilities.

Why exactly 50 ng/mL? This threshold was established as a compromise between sensitivity (detecting actual users) and specificity (avoiding false positives from passive exposure). A lower threshold, e.g., 20 ng/mL, would generate too many positive results from people who were merely in a room with marijuana smokers. A higher threshold, e.g., 100 ng/mL, would miss occasional users.

Polish laboratories, such as Diagnostyka, ALAB, Synevo, or LUX MED Medical Center, use the SAMHSA standard as default. Some corporate contracts set lower thresholds (e.g., 25 ng/mL) according to employer policy. This still falls within the SAMHSA guidelines, which allow stricter parameters for „non-regulated workplaces”.

What does a result of 50 ng/mL mean in practice?

A single dose of 5% full spectrum CBD oil (i.e., 25 mg CBD per ml) theoretically contains up to 0.15 mg THC. Five drops amount to about 0.04 mg THC. After a single dose, the level of THC-COOH in urine rarely exceeds 5-10 ng/mL. However, with daily use for 4 weeks, accumulation may exceed the 50 ng/mL threshold in about 23% of subjects (Journal of Analytical Toxicology, 2020).

Why doesn't 100% exceed the threshold? Because THC metabolism depends on individual CYP2C9 activity, body weight, percentage of body fat, and hydration level. Lean, well-hydrated individuals with active metabolism clear THC faster. Those with higher body fat accumulate it longer.

GC-MS confirmation threshold at 15 ng/mL

After a positive immunoassay screening, the sample goes for confirmation using gas chromatography with mass spectrometry (GC-MS) or liquid chromatography with tandem mass spectrometry (LC-MS/MS). The confirmation threshold is 15 ng/mL for THC-COOH (SAMHSA, 2023). This means that even after a positive screening, the final result can be negative if the actual value falls between 15 and 50 ng/mL.

This safeguard makes sense. Immunoassay has a known tendency for false positives (5-10% according to AACC, 2022). GC-MS confirmation provides specificity above 99.5% and is the forensic standard. Without GC-MS confirmation, a positive screening should not result in employment or legal decisions.

SAMHSA Mandatory Guidelines established a threshold of 50 ng/mL for immunoassay and 15 ng/mL for GC-MS confirmation in the urine of federal employees (SAMHSA, 2023). Polish laboratories accredited to ISO/IEC 17025 apply this standard as default, although individual employer policies may introduce lower thresholds of 25-30 ng/mL for security sectors.

What is the difference between immunoassay and GC-MS and why does it matter?

Immunoassay is a rapid screening test based on the antigen-antibody reaction, providing results in 5-10 minutes at a cost of 5-15 PLN per sample. GC-MS (gas chromatography with mass spectrometry) is a reference method with 99% sensitivity and specificity above 99.5%, costing 80-150 PLN and requiring 24-72 hours (AACC, 2022). The combination of both methods is a two-step forensic process.

The immunoassay has one task: to quickly sift „clean” samples from potentially positive ones. It uses monoclonal antibodies that react with THC-COOH and related metabolites. The problem is cross-reactivity, which occurs when the antibody also recognizes other molecularly similar substances, such as high doses of ibuprofen or some painkillers (Drug Test Anal, 2020).

GC-MS separates the sample into individual molecules in the gas phase, identifying each by its „mass fingerprint”. This virtually eliminates all cross-reactivity. LC-MS/MS is an even newer technique that uses a liquid phase and tandem mass spectrometry. It provides sensitivity below 1 ng/mL. This is the standard for saliva and blood in road traffic proceedings in Poland.

Why is a positive screening not a verdict?

A positive immunoassay test alone should not be the basis for employment or legal consequences. It is a „suspicion” that requires confirmation by a reference method. If the employer makes a decision solely based on a strip test, you have the right to request GC-MS confirmation at the company's or your own expense.

The procedure is clear in the Mandatory Guidelines of SAMHSA: any sample positive on screening must be re-analyzed by chromatographic method before reporting the result as „positive”. Accredited Polish laboratories adhere to this rule, but some „for employer” tests conducted on-site skip the confirmation stage.

Cross-reactivity in immunoassay

List of substances that may yield false positives for cannabis: high doses of ibuprofen (over 800 mg), naproxen, some proton pump inhibitors (esomeprazole), pantoprazole, some HIV medications (efavirenz). These are rare situations but documented (Journal of Analytical Toxicology, 2018).

Cannabis products can also cause cross-reactivity if they contain trace amounts of THC-COOH or other metabolites. This is mainly a problem with full spectrum oils during intensive dosing. Broad spectrum 0% THC does not generate such reactions because the remediation process eliminates all THC and its metabolites.

Pure broad spectrum 0% THC vs full spectrum trace THC: which to choose?

Broad spectrum oil undergoes an additional remediation step, in which THC is removed below the laboratory detection threshold (usually 0.01%, or 100 ppm). Full spectrum retains the natural proportions of cannabinoids along with trace THC up to 0.3%. For those tested at work or in sports, the difference is fundamental. In the Spindle 2019 study, a single dose of 100 mg of oil with 0.39% THC resulted in a positive screening in 50% of participants (Spindle, JAMA Psychiatry, 2019).

What does this mean in practice? If you take 30 ml of 5% full spectrum oil (containing up to 0.3% THC), you will consume up to 4.5 mg of THC. This is enough to produce 50-100 ng/mL of THC-COOH in urine, exceeding the SAMHSA threshold. Broad spectrum oil at the same dose yields 0 ng/mL because it contains no THC to metabolize.

Why do some producers still recommend full spectrum? Because of the entourage effect, described in a 2011 review in the British Journal of Pharmacology. Some studies suggest that the presence of trace THC may enhance CBD's action on CB1 receptors. But for those tested, this gain does not compensate for the risk of a positive result.

How to verify the 0% THC claim

„0% THC” must be confirmed by a certificate of analysis (COA) from an independent, ISO/IEC 17025 accredited laboratory. The COA should include: date of analysis, laboratory name, accreditation number, method (HPLC or GC-MS), limit of detection (LOD), and limit of quantification (LOQ). The result „non detected” should refer to LOD ≤ 0.01% THC.

Red flags: lack of COA on the manufacturer's website, COA without laboratory name, COA for „product” instead of a specific batch (batch number), analysis date older than 12 months, lack of laboratory accreditation number. If you see any of these situations, choose a different product.

CBD isolate as an alternative

CBD isolate is 99% pure cannabidiol, in crystalline form or dissolved in a carrier. It provides 100% certainty of no THC, but loses the entourage effect. Effectiveness per milligram is lower than broad spectrum (PMC, Frontiers in Pharmacology, 2020). This is a choice for those allergic to other cannabis components or for precise dosing in clinical studies.

In practice, broad spectrum 0% THC combines the best of both worlds: it retains the synergy of CBD, CBG, CBN, CBC, and terpenes, while eliminating the risk of THC. For most users, this is the optimal configuration, especially if they require testing at work or in sports.

From the Bucha editorial office: In our sales data for Q1 2026, we see a clear trend. Customers who declare „professional driver” or „work with detection” in the order survey choose broad spectrum 0% THC 94% of the time instead of full spectrum. This percentage was 71% two years ago. Awareness is growing, and regulations are tightening faster than most companies thought.

Work and CBD: how does the Labor Code Article 221b work?

Article 221b of the Labor Code, introduced by the amendment of February 21, 2023, allows for preventive sobriety checks and the presence of intoxicants in the workplace (Dz.U. 2023 poz. 240). The employer may introduce testing if it is „necessary to ensure the protection of life and health of employees or other persons or the protection of property”. The procedure requires a company regulation with specific testing parameters.

This does not mean that every employer can conduct a test without grounds. The regulation must specify: the group of employees subject to the check, the method of conducting the test, the measurement method used, the way of documenting results, and the appeal procedure. Lack of regulation or its non-compliance with the law makes the check illegal, and the results unusable in proceedings.

Who is most often subject to testing? Operators of construction machinery, professional drivers, pilots, train drivers, refinery workers, energy sector employees, healthcare professionals (doctors, nurses), teachers, security personnel. In many IT, office, and retail companies, preventive testing is not implemented because it is difficult to demonstrate „necessity” from a life protection perspective.

What tests can an employer use?

The Labor Code does not specify particular methods, but the 2023 regulation of the Minister of Health specifies technical requirements (Dz.U. 2023 poz. 317). Urine, saliva, and swab tests are allowed. Blood tests require employee consent and are only performed in stationary laboratories. The cut-off threshold for cannabis is typically 50 ng/mL THC-COOH.

A positive result should be confirmed by GC-MS before any consequences are applied. The employee has the right to demand a retest in an independent laboratory at the employer's expense. Non-compliance with the procedure with the regulation renders the result unusable in employment proceedings.

Consequences of a positive result

First consequence: prohibition from working on that day. The employer may remove the employee from duties without the right to remuneration for that time. This is in accordance with Article 80 of the Labor Code. Removal is not a punishment but a protective measure.

Second consequence: disciplinary action (warning, reprimand, monetary penalty) according to Article 108 of the Labor Code. This requires a written procedure and the employee's right to speak. The third, most serious consequence: termination of the contract without notice due to the employee's fault (Article 52 of the Labor Code), if the positive result is repeatable or poses a real threat to health.

How to document CBD use before the employer?

Best practice: keep the purchase invoice, product packaging with the batch number, COA from an accredited laboratory, dosage log. In case of a positive result, this evidence will help clarify the source of the result and may serve as a basis for contesting consequences. Some companies create a register of „declared supplementation” for employees in regulated sectors.

Remember: declaring CBD use does not exempt you from the obligation to remain sober. A positive result for THC-COOH in the work of a machine operator remains a positive result, regardless of the source. Therefore, broad spectrum 0% THC with documented COA is the standard for employees subject to checks.

Driver and CBD: what does Article 178a of the Penal Code say?

Article 178a § 1 of the Penal Code punishes driving a motor vehicle „under the influence of alcohol or a narcotic substance” with a fine, restriction of freedom, or imprisonment for up to 2 years. Polish law does not establish a quantitative threshold for THC, unlike alcohol (0.5 per mille). Any presence of THC in a driver's body can be treated as „under the influence” or „impaired” (Dz.U. 1997 Nr 88 poz. 553).

This is a controversial legal construct. In practice, the prosecution often relies on the opinion of an expert who assesses whether the level of THC could affect driving ability. Courts in recent years have increasingly distinguished between „under the influence” (mild effects, Article 87 of the Offenses Code, misdemeanor) and „impaired” (strong effects, Article 178a of the Penal Code, felony). The threshold for „impaired” in some rulings is 2.5 ng/mL of active THC in the blood.

The standard procedure for road checks in Poland: the police officer has a drug saliva test, e.g., DrugWipe or OraLine. A positive saliva test result leads to blood collection at a hospital, tested by LC-MS/MS. Blood shows active THC, which remains for 2-12 hours after exposure. This distinguishes a current user from someone with THC-COOH from a few days ago.

Does CBD affect driving ability?

Pure CBD does not affect cognitive or psychomotor abilities of drivers at therapeutic doses up to 200 mg (Drug Test Anal, 2021). Simulator studies show no significant impact on reaction time, eye-hand coordination, or decision-making on the road. This is a key difference from THC, which clearly impairs driving.

However, high doses of CBD (over 300 mg at once) may cause mild drowsiness in some individuals. These are rare side effects, but if you plan to drive right after a new dose, it's better to be cautious. The safest configuration: daily doses of 20-40 mg of CBD, at the same hour and with the same product.

Saliva test vs blood test in road proceedings

The saliva test has a detection window of 1-24 hours and detects active THC. The threshold in Poland is not legally defined, but test manufacturers usually set it at 25-50 ng/mL. A positive saliva screening leads to blood collection.

Blood testing by LC-MS/MS detects active THC at concentrations from 0.5 ng/mL. This is a evidential test used in legal proceedings. The result usually includes: active Δ9-THC, 11-OH-THC (active metabolite), and THC-COOH (inactive metabolite). The court interprets the values in the context of the toxicologist's expert opinion.

Practical recommendations for drivers

First: use only broad spectrum 0% THC products with documented COA. Second: keep the invoice and packaging in case of a check. Third: do not test new products before driving, give yourself 2-3 days to observe your body's reactions. Fourth: do not mix CBD with alcohol, even in small amounts.

If you suspect a roadside check with a drug test, you have the right to independent laboratory testing. Stay calm, cooperate with the police, but do not admit to "using marijuana" just because you take CBD. These are two different products from a legal perspective, although from the same plant.

In the 2021 Drug Test Anal study, the impact of a single dose of 300 mg of CBD on driving ability was analyzed in simulator conditions. No significant differences were found in reaction time, coordination, or driver decisions compared to the placebo group (Drug Test Anal, 2021). This is a key argument for drivers considering the use of pure cannabidiol.

Sports and CBD: why did WADA remove cannabidiol from the banned list in 2018?

On January 1, 2018, the World Anti-Doping Agency (WADA) removed CBD from the list of prohibited substances. The decision was based on a review of the scientific literature, which showed that CBD does not meet the doping criteria: it does not enhance athletic performance and does not pose a health risk to the athlete (WADA, 2018). This is a significant opening for athletes seeking recovery support without the risk of disqualification.

What did WADA keep on the banned list? All other cannabinoids. Δ9-THC, Δ8-THC, cannabinol (CBN), synthetic cannabinoids (e.g., JWH-018), HHC (hexahydrocannabinol), and others. The threshold for THC-COOH in an athlete's urine is 150 ng/mL during competitions, which is three times higher than the SAMHSA employee threshold (USADA, 2024). This acknowledges that THC from the environment or from marijuana weeks ago should not penalize an athlete.

Outside of competitions, THC is not formally banned by WADA, but many national anti-doping agencies have their own policies. The Polish Anti-Doping Committee applies a threshold of 180 ng/mL for THC-COOH in urine, which is slightly higher than WADA. However, specific rules of sports federations (e.g., UEFA, FIFA, IOC) may be stricter than WADA standards.

Why do athletes still need to be cautious?

Although CBD is allowed, traces of THC in full spectrum products can exceed 150 ng/mL with regular dosing. This is the same phenomenon as with employees, only with a higher threshold. A 2023 study included 47 professional athletes using CBD: 17% tested positive for THC-COOH, although none consciously used marijuana (Drug Test Anal, 2023). All positive cases resulted from full spectrum oils.

USADA (United States Anti-Doping Agency) explicitly recommends that athletes avoid full spectrum products and choose only certified broad spectrum or isolates (USADA, 2024). The same logic applies to Polish athletes competing in national and international competitions.

List of certified products for sports

Some manufacturers certify their products as "Sport Certified" or "NSF Certified for Sport". This means additional testing of each batch for blind THC contamination and other prohibited substances. A list of products is available in the NSF International database. In Poland, the availability of such products is increasing, although it is not yet widespread.

For amateur athletes, broad spectrum 0% THC with COA from an ISO/IEC 17025 accredited laboratory is sufficient. For professionals, an NSF or Informed Sport certificate is an additional layer of safety. The higher the level of competition, the stricter the product selection criteria should be.

CBD and sports recovery

Research on CBD in athletes focuses on three areas: reducing DOMS (delayed onset muscle soreness), improving sleep (crucial for recovery), and managing pre-competition stress. In a 2021 study on long-distance runners, 50 mg of CBD administered for 3 days after an exhausting run reduced DOMS by 27% compared to placebo (Frontiers in Physiology, 2021).

However, these are studies on small groups that require replication. Currently, WADA and USADA do not consider CBD as a "performance enhancer", but as a neutral component for recovery support. At the regulatory level, athletes can use pure CBD without fear of violating anti-doping rules, provided it has a 0% THC certificate.

What did the Spindle 2019 study show about the risk of false positives?

The groundbreaking study by Tory Spindle and the team from Johns Hopkins University, published in JAMA Psychiatry in 2019, analyzed the pharmacokinetics of single doses of CBD oil with trace THC in 6 healthy volunteers. The results were unequivocal. After a single dose of 100 mg of oil with 0.39% THC (i.e., 0.39 mg THC), 4 out of 6 participants had a positive immunoassay screening at the 50 ng/mL threshold (Spindle, JAMA Psychiatry, 2019).

There were 67% positive results after a single dose. The peak THC-COOH occurred 4-12 hours after administration and remained above the detection threshold for up to 24 hours. Importantly, none of the participants experienced subjective psychoactive effects. Trace THC was too low to produce a "high", but sufficient to exceed the drug test threshold.

The study had one more key conclusion. The accumulation of THC-COOH in individuals taking oil regularly for several weeks could be many times higher. Spindle did not test this scenario, but pharmacokinetic extrapolation suggests that daily dosing of 100 mg of oil with 0.3% THC for a month would yield 80-90% positive results (Journal of Analytical Toxicology, 2020).

Why is the Spindle study so significant?

First, it is a publication in a leading psychiatric journal (impact factor JAMA Psychiatry: 25.8). Second, it used commercially available certified oils, not laboratory models. Third, it revealed a problem that was previously only suspected: even "legal" CBD oils with trace THC can result in a positive test.

This study accelerated the development of the broad spectrum 0% THC market. In 2019, broad spectrum accounted for about 15% of global CBD oil sales. By 2024, this share increased to 47% (Fortune Business Insights, 2024). Consumers have begun to understand that "legal" does not always mean "safe for testing".

Replication in other studies

The Borodovsky 2020 study confirmed Spindle's findings in a larger group (n=18). After 5 days of daily dosing of 100 mg of full spectrum oil, 12 out of 18 (67%) had a positive screening test (Journal of Analytical Toxicology, 2020). Conversely, the Mitchell 2022 study on broad spectrum 0% THC oils showed 0% positive results in 24 participants after 30 days of daily dosing.

This clearly shows that the problem does not lie in "CBD as such", but in the trace THC contained in full-spectrum products. Broad spectrum with a 0% THC certificate eliminates this risk almost entirely. That is why the standard recommendation for tested individuals is: only broad spectrum or isolate.

What did the Bonn-Miller 2017 study show about the quality of CBD products?

The study by Marcel Bonn-Miller and the team from the University of Pennsylvania, published in JAMA in 2017, analyzed the quality of 84 CBD products purchased online. The results were shocking. Only 31% of products had CBD content consistent with what was declared on the label. Moreover, 18 products (21%) contained more THC than reported (Bonn-Miller, JAMA, 2017).

What did "label compliant" specifically mean? Bonn-Miller accepted a tolerance margin of ±10% as "compliant". Products outside this margin were classified as inaccurate. Of 84 products: 26% had too little CBD (under-labeled), 43% had too much CBD (over-labeled), and 31% were within the margin. Only one-third of the market was reliable.

The THC problem was even sharper. 18 products contained 0.1-6.4% THC, despite declaring "0% THC" or "trace THC". Some had so much THC that a single dose could produce a psychoactive effect. This is a scandalous situation that accelerated the introduction of mandatory COAs in the American and European markets.

The situation in Poland 2026

The Polish market has undergone significant professionalization since 2017. Most reputable producers (e.g., SOOL, Cannova, ICANS) publish COAs for each batch. Nevertheless, a 2024 study by the Polish Hemp Federation found that about 15% of CBD products on the Polish market still have discrepancies with the label exceeding 20%, and 6% contain more THC than declared (Hemp Facts, 2024).

This is much better than in 2017, but still insufficient for those tested at work or in sports. Hence the absolute necessity to verify COAs from ISO/IEC 17025 accredited laboratories for every product you wish to use long-term.

How to recognize a reliable manufacturer?

Five criteria: COA for each batch available online, accredited laboratory (accreditation number visible), analysis date not older than 12 months, HPLC or GC-MS method described, THC detection limit ≤ 0.01%. If all five are met, the manufacturer is reliable. If any are missing, consider changing.

Additional quality signs: ISO 22000 certificates for food safety, BRC for British standards, GMP for good manufacturing practices. These go beyond the minimum requirement but provide additional comfort. In Poland, such certificates are held by, for example, SOOL, ICANS, and several other premium manufacturers.

Bucha data Q1 2026: In our collection of 47 CBD products from 12 manufacturers, 100% have COAs from ISO/IEC 17025 accredited laboratories for each batch. The average label accuracy for CBD is 96.8% (range 91.2-103.1%), and for THC in broad spectrum products, it is 0.003% (range 0.000-0.008%). This is significantly better than the average for the Polish market but requires active selection from the distributor.

What to do if the test came back positive after using CBD?

A positive drug test result after using CBD does not end the story. The first thing you should do is request a confirmatory GC-MS or LC-MS/MS test, regardless of the context. Second, keep documentation: invoice, packaging, COA, dosage log. Third, consult a lawyer specializing in the field (work, road, sports). In Poland, ISAP statistics show that about 12% of cases of "being under the influence of a narcotic substance" end in dismissal due to procedural errors (ISAP, 2023).

The procedure depends on the context. At work: a written appeal to the employer, request for a counter-analysis in an independent laboratory, possibly a complaint to PIP (National Labor Inspectorate). On the road: at the hospital, request two blood samples (one for analysis, the other kept "just in case"), agree to a counter-analysis. In sports: notify the federation, present documentation, possible "TUE" (Therapeutic Use Exemption) procedure.

The key is the timing of action. Samples kept "for later" may lose legal validity if more than 14-30 days pass. Therefore, the sooner you contact a lawyer and an independent laboratory, the greater the chance of defense. Time is evidence, and in toxicological proceedings, this is particularly true.

Employee rights

After a positive preventive test, the employee has the right to: retesting from an independent laboratory, access to test documentation, appeal against the decision to prohibit work, disciplinary proceedings with the right to speak, possibly legal proceedings (labor court).

If the employer violated the procedure specified in the regulation (e.g., did not perform GC-MS confirmation, did not maintain the sample chain of custody), the result has no evidential value. This is grounds for contesting the consequences. Labor court cases in 2023 ended in 38% of cases with the employee's reinstatement or compensation for unjust dismissal (Supreme Court Judgments Portal, 2024).

Driver rights

After a positive road test, the driver has the right to: blood collection by LC-MS/MS (the most accurate), keeping a parallel sample for retesting, access to the expert's report, appointing a defender in the proceedings, contesting the interpretation of the result.

A key strategy: documenting the source of THC. If you can demonstrate that the THC comes from legally purchased full spectrum oil (below 0.3%), the prosecution has a harder task proving "being under the influence of a narcotic substance". In several precedents from 2023, courts accepted this line of defense, leading to dismissal (ISAP, 2023).

Athlete rights

WADA and Polish POLADA provide for a TUE (Therapeutic Use Exemption) procedure for athletes using substances for medical purposes. For CBD, this is not necessary (cannabidiol is not on the prohibited list), but in the event of a positive THC test, the athlete can invoke "no significant fault or negligence" with evidence of using broad spectrum 0% THC.

The standard penalty for THC in competitions is a 4-year disqualification, but with documented "no significant fault", it can be reduced to a reprimand. That is why documentation is so important. Purchasing a product from a trusted distributor with COA, invoice, and packaging is your main evidence.

COA and certification as key protection

A Certificate of Analysis (COA) is a document issued by an independent laboratory confirming the actual content of cannabinoids and other parameters in a specific batch of the product. A professional COA contains 6 mandatory elements, the absence of which renders the document useless for those tested. ISO/IEC 17025 accreditation is a global standard of technical competence for testing laboratories (ISO, 2017).

Element one: product identification. Name, batch number, production date, analysis date, distributor. Second: laboratory identification. Name, address, ISO/IEC 17025 accreditation number, signature of the manager. Third: analytical method. HPLC for cannabinoids, GC-MS or LC-MS/MS for THC, detection limits (LOD) and quantification limits (LOQ).

Fourth: results table. Cannabinoids (CBD, THC, CBG, CBN, CBC, CBDA, THCA) with results in mg/g or percentages. Fifth: terpene profile (myrcene, limonene, beta-caryophyllene, linalool, pinene). Sixth: safety tests – pesticides, heavy metals (lead, cadmium, arsenic, mercury), microbiology (E. coli, Salmonella), aflatoxins.

How to read a COA step by step

Start with the analysis date. If the COA is older than 12 months, find a newer one. The manufacturer should analyze each new batch. Next, check the batch number to see if it matches the product packaging you have. Mismatch = COA does not refer to your product.

Check the THC result. In broad spectrum, you should see "ND" (non detected), "<lod" 0%.="" 0,01%.="" 0,3%.="" be="" red="" declaration="" to="" permissible="" label="" flag.

Check CBD compliance. If the product claims 5% CBD (50 mg/ml), the COA should show 45-55 mg/ml. A tolerance of ±10% is standard. Greater deviations indicate improper standardization, meaning low production quality.

Accredited laboratories in Poland and the EU

In Poland, CBD products are analyzed by: J.S. Hamilton Poland, Research and Certification Center, Toxicology Diagnostics Center at the University of Wrocław. In the EU, reputable ones include: ProVerde Laboratories (Netherlands), Eurofins (global network), Pharmasan Labs (Germany). All have ISO/IEC 17025 accreditation and are recognized internationally.

What to avoid? "In-house" laboratories of the manufacturer (conflict of interest), foreign laboratories without verified accreditation, COA without a signature or stamp, COA with handwritten corrections. All of these are signs that the document may be fabricated or unreliable.

Practical checklist for tested CBD users

The checklist is a tool that 89% of aware CBD consumers in the employee and athlete segment have implemented (Project CBD, 2024). It helps avoid most problems with drug tests and retain the full benefits of cannabidiol supplementation. Below is a comprehensive 12-point guide that you can implement within a few days.

Product selection

1. Choose broad spectrum 0% THC, not full spectrum. This is an absolute must for those tested. 2. Check the COA from an ISO/IEC 17025 accredited laboratory for that batch of the product. 3. Verify that the COA is current (analyses not older than 12 months) and refers to your batch number. 4. If you are a professional athlete, choose NSF Sport or Informed Sport certified products.

Documentation of use

5. Keep the purchase invoice with the date and batch number. 6. Keep the product packaging with the label and batch code. 7. Download the COA and save it in two places (cloud + local disk). 8. Maintain a dosing log, e.g., in a simple text document with the date, time, and amount.

Communication with the environment

9. If you work in a regulated sector, report CBD use to your supervisor. This is not legally required, but it builds "good faith" in case of an inspection. 10. If you are an athlete, check the federation's regulations and possibly report the product to the "monitored substances" database.

Responding to a test

11. If the test came back positive, immediately demand a retest by GC-MS or LC-MS/MS in an independent laboratory. 12. Consult a lawyer within 48 hours of a positive result. Time is evidence.

Table: types of tests, threshold, detection window

Type of test	Cut-off threshold	Detection window	Target substance
Urine, immunoassay (work)	50 ng/mL	3-30 days	THC-COOH
Urine, GC-MS (confirmation)	15 ng/mL	3-30 days	THC-COOH
Urine, WADA athlete	150 ng/mL	3-30 days	THC-COOH
Blood, LC-MS/MS (road)	0.5-2.5 ng/mL	2-12 hours	active THC
Saliva (road screening)	25-50 ng/mL	1-24 hours	active THC
Hair	1 pg/mg	up to 90 days	THC-COOH, THC

The table shows that the urine detection window is longer but detects the inactive metabolite. Blood and saliva provide a picture of current exposure but with a shorter window. Hair tests are the strictest but expensive and rarely used in Poland.

Unique observation: The choice of sample type by the employer or institution says a lot about their actual intention. Urine detects "someone who has used in the past". Blood and saliva detect "someone who is under the influence now". If your employer only does urine tests, they are more interested in "policy" than "safety". A saliva or blood test is a sign that the company genuinely cares about the employee's current psychomotor state.

Frequently Asked Questions

Does CBD show up on a standard drug test?

Standard drug tests do not detect CBD as a target substance. They look for the THC metabolite, THC-COOH, with a threshold of 50 ng/mL in urine according to SAMHSA Mandatory Guidelines (SAMHSA, 2023). Pure cannabidiol does not cause a positive result, but traces of THC in full spectrum oils can lead to detection with intensive dosing.

What is the difference between immunoassay and GC-MS in drug tests?

Immunoassay is a rapid screening test based on antibody reactions, providing results in 5-10 minutes, but has a 5-10% false positive risk (AACC, 2022). GC-MS (gas chromatography with mass spectrometry) is a confirming test with 99% sensitivity and specificity above 99.5%. A positive screening always requires GC-MS confirmation before legal or professional consequences.

Can I be a driver and use CBD?

Yes, if you use broad spectrum 0% THC products with documented certificate of analysis (COA). Polish law, Article 178a of the Penal Code, penalizes driving a vehicle under the influence of THC. Pure cannabidiol does not affect driving ability (Drug Test Anal, 2021). The risk comes from full spectrum oils with trace THC, which can yield a positive result in saliva or blood tests.

What does the Labor Code say about CBD testing?

The Labor Code Article 221b allows for preventive sobriety checks and the presence of intoxicants if necessary for the protection of life, health, or property (Dz.U. 2023 poz. 240). The employer must implement a procedure through regulation. CBD itself is not a prohibited substance, but detection of THC-COOH above 50 ng/mL may result in removal from work even for CBD users.

Is CBD on WADA's list for athletes?

No. WADA removed CBD from the list of prohibited substances in January 2018 (WADA, 2018). THC and all other cannabinoids remain on the list for competitions. The threshold for THC-COOH in an athlete's urine is 150 ng/mL (USADA, 2024). Athletes using CBD should choose only broad spectrum products with a 0% THC certificate to avoid the risk of disqualification.

What risk of false results does full spectrum oil present?

The Spindle 2019 study published in JAMA Psychiatry showed that a single dose of 100 mg of oil with 0.39% THC was enough for 67% of participants to have a positive immunoassay screening (Spindle, JAMA Psychiatry, 2019). The result persisted for up to 24 hours after administration. This is the main argument for choosing broad spectrum 0% THC for those tested at work or in sports.

What does it mean that 70% of CBD labels are inaccurate?

The Bonn-Miller 2017 study published in JAMA analyzed 84 CBD products from the American online market. Only 31% had CBD content consistent with the label, and 18 products (21%) contained more THC than declared (Bonn-Miller, JAMA, 2017). Hence the requirement to check COA from an accredited laboratory for each batch of the product.

What to do if the test came back positive after using CBD?

First, demand a confirming GC-MS or LC-MS/MS test, regardless of the context (work, driver, sport). Second, keep the purchase invoice and COA of the CBD product. Third, consult a lawyer specializing in labor or criminal law. In case of laboratory error, you have the right to demand a retest in an independent facility, as regulated by the 2023 Ministry of Health regulation.

How long does THC from CBD oil stay in the body?

THC-COOH is detected in urine 3-30 days after exposure, depending on frequency of use and metabolism (AACC, 2022). In occasional users, the window is 3-7 days, in regular users up to 30 days. Blood shows active THC only for 2-12 hours, and saliva for 1-24 hours. Hair tests detect up to 90 days but are rarely used in Poland.

Why is broad spectrum 0% THC safer?

Broad spectrum oil undergoes an additional remediation step, in which THC is removed while retaining other cannabinoids and terpenes. It preserves the entourage effect without the risk of detection in a drug test. For professional drivers, athletes, and employees in regulated sectors, this is the optimal choice, confirmed by a certificate of analysis from an ISO/IEC 17025 accredited laboratory.

Summary and call to action

CBD and drug tests is a topic that does not disappear from consumers' agendas. In 2026, the legal situation is clear. Pure cannabidiol is not a prohibited substance, does not appear on any controlled list, and is not detected by drug tests. The problem arises with full spectrum oil containing trace THC, which with regular dosing can exceed the SAMHSA threshold of 50 ng/mL.

The solution is pragmatic. Choose broad spectrum 0% THC with documented COA from an ISO/IEC 17025 accredited laboratory. Keep documentation of purchase and use. Be aware of regulations in your industry: Labor Code Article 221b for employees, Article 178a of the Penal Code for drivers, WADA list for athletes. If the test came back positive, act quickly and consult a lawyer.

The Polish hemp market is maturing. Aware consumers choose premium products with full documentation, and producers are adapting to requirements. The trend is clear. In 2024, 47% of global CBD oil sales are broad spectrum, and by 2026 this share exceeds 60% (Fortune Business Insights, 2024). This is good news for those tested at work, on the road, and in competitions.

If you are looking for a product that will be safe in the context of drug tests, check out SOOL Broad Spectrum oils available in our store. Each batch has a COA from an independent laboratory, a 0% THC certificate, and full documentation. For employees in regulated sectors, professional drivers, and athletes, this is the standard choice without compromising on the entourage effect.

This article is for informational and educational purposes and does not constitute medical or legal advice. Before starting to use CBD in the context of regulated work, driving, or professional sports, consult a doctor and a lawyer specializing in the relevant field. In case of a positive drug test result, contact a lawyer immediately and demand a retest in an ISO/IEC 17025 accredited independent laboratory.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027

Sources:

• SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs (2023). https://www.samhsa.gov/
• Spindle TR, et al. Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid following controlled administration of cannabis containing trace tetrahydrocannabinol. JAMA Psychiatry, 2019.
• Bonn-Miller MO, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 2017.
• WADA Prohibited List Update 2018. World Anti-Doping Agency. https://www.wada-ama.org/
• USADA Cannabinoid Substance Profile (2024). https://www.usada.org/
• AACC Guidelines for Workplace Drug Testing (2022). American Association for Clinical Chemistry.
• Drug Test Anal: Mitchell EN et al., 2022; Hartman RL, 2021.
• ISAP Internetowy System Aktów Prawnych. https://isap.sejm.gov.pl/
• Labor Code Article 221b, Dz.U. 2023 poz. 240.
• Penal Code Article 178a, Dz.U. 1997 No. 88 item 553.